Literature DB >> 8018376

Relationship of DNA ploidy and S-phase fraction to survival after first recurrence of breast cancer.

O Stål1, J M Carstensen, S Wingren, L E Rutqvist, L Skoog, C Klintenberg, B Nordenskjöld.   

Abstract

Flow cytometry was performed on frozen specimens from the primary tumour of 184 women with recurrent breast cancer. No significant association was seen between DNA ploidy and the other prognostic factors investigated. Patients with a high S-phase fraction had more often a negative estrogen receptor (ER) status and a short disease-free interval. A shorter survival after disease recurrence was seen both in patients with DNA aneuploid tumours and among those with a high S-phase fraction. Patients with DNA tetraploid tumours showed the longest survival after recurrence. In this subgroup, half of the patients survived more than 3 years after recurrence and the estimated survival rate at 10 years was 17%. In a Cox's regression analysis including 116 patients, site of recurrence, number of positive nodes at time of primary operation, size and ER content of the primary tumour as well as DNA ploidy showed additional prognostic value.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018376     DOI: 10.3109/02841869409098439

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Multiparameter DNA content analysis identifies distinct groups in primary breast cancer.

Authors:  J H S Dayal; M J Sales; W E Corver; C A Purdie; L B Jordan; P R Quinlan; L Baker; N T ter Haar; N R Pratt; A M Thompson
Journal:  Br J Cancer       Date:  2013-02-14       Impact factor: 7.640

Review 2.  Therapeutic monoclonal antibodies in oncology.

Authors:  Adam P Levene; Guminder Singh; Carlo Palmieri
Journal:  J R Soc Med       Date:  2005-04       Impact factor: 18.000

3.  Met and its ligand HGF are associated with clinical outcome in breast cancer.

Authors:  Cynthia Veenstra; Gizeh Pérez-Tenorio; Anna Stelling; Elin Karlsson; Sanam Mirwani Mirwani; Bo Nordensköljd; Tommy Fornander; Olle Stål
Journal:  Oncotarget       Date:  2016-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.